FY2025 Earnings Estimate for Q32 Bio Issued By HC Wainwright

Q32 Bio Inc. (NASDAQ:QTTB) – Research analysts at HC Wainwright issued their FY2025 earnings per share (EPS) estimates for Q32 Bio in a report released on Wednesday, February 25th. HC Wainwright analyst J. Pantginis forecasts that the company will earn ($2.91) per share for the year. HC Wainwright has a “Buy” rating and a $13.00 price target on the stock. The consensus estimate for Q32 Bio’s current full-year earnings is ($12.32) per share. HC Wainwright also issued estimates for Q32 Bio’s Q4 2025 earnings at ($0.63) EPS, FY2026 earnings at ($2.53) EPS, FY2027 earnings at ($2.43) EPS and FY2028 earnings at ($2.19) EPS.

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Q32 Bio in a research note on Friday, January 9th. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $14.00.

Q32 Bio Stock Down 4.2%

Shares of QTTB stock opened at $4.56 on Friday. Q32 Bio has a 12-month low of $1.35 and a 12-month high of $6.37. The company has a market capitalization of $56.11 million, a PE ratio of -1.33 and a beta of 0.16. The firm has a 50 day moving average price of $3.81 and a two-hundred day moving average price of $2.90.

Insider Buying and Selling at Q32 Bio

In other Q32 Bio news, CFO Lee Kalowski sold 9,072 shares of Q32 Bio stock in a transaction on Tuesday, December 2nd. The stock was sold at an average price of $3.46, for a total value of $31,389.12. Following the completion of the transaction, the chief financial officer directly owned 39,938 shares of the company’s stock, valued at $138,185.48. The trade was a 18.51% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Jodie Pope Morrison sold 22,506 shares of the stock in a transaction on Tuesday, December 2nd. The stock was sold at an average price of $3.46, for a total value of $77,870.76. Following the sale, the chief executive officer directly owned 99,000 shares in the company, valued at approximately $342,540. This trade represents a 18.52% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 48,284 shares of company stock valued at $184,604 over the last ninety days. Insiders own 40.00% of the company’s stock.

Institutional Investors Weigh In On Q32 Bio

A number of large investors have recently bought and sold shares of the company. Monaco Asset Management SAM raised its position in shares of Q32 Bio by 17.1% in the 2nd quarter. Monaco Asset Management SAM now owns 591,937 shares of the company’s stock valued at $882,000 after buying an additional 86,486 shares in the last quarter. Opaleye Management Inc. bought a new position in Q32 Bio in the fourth quarter valued at approximately $708,000. Geode Capital Management LLC increased its stake in Q32 Bio by 19.9% in the fourth quarter. Geode Capital Management LLC now owns 106,113 shares of the company’s stock valued at $352,000 after acquiring an additional 17,617 shares during the last quarter. Renaissance Technologies LLC raised its position in Q32 Bio by 110.6% during the fourth quarter. Renaissance Technologies LLC now owns 99,600 shares of the company’s stock valued at $331,000 after purchasing an additional 52,300 shares in the last quarter. Finally, Jane Street Group LLC bought a new stake in Q32 Bio during the second quarter worth $69,000. 31.32% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Q32 Bio

Here are the key news stories impacting Q32 Bio this week:

• Positive Sentiment: HC Wainwright initiated coverage with a Buy rating and a $13 price target, providing a long‑term constructive view that can support upside versus current levels. HC Wainwright Begins Coverage on Q32 Bio
• Neutral Sentiment: HC Wainwright published a multi‑year forecast showing improving EPS over time and an eventual transition to modest profitability in FY2030 (EPS $0.11), which is a positive directional signal but depends on successful clinical and commercial execution.
• Negative Sentiment: The analyst model shows substantial near‑term losses: Q4 2025 EPS of ($0.63) and FY2025–FY2028 EPS ranging from about ($2.91) to ($2.19). These projected deficits increase financing and execution risk and likely weigh on short‑term investor sentiment.
• Negative Sentiment: Consensus full‑year earnings remain deeply negative (current consensus ~($12.32) per share), indicating the market and other analysts expect much larger near‑term losses than HC Wainwright’s more optimistic runway—this divergence may temper the impact of the Buy rating.

About Q32 Bio

Q32 Bio Inc, a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis.